Quality of life in Cushing’s syndrome

Arnaldi, 2003, Diagnosis and complications of Cushing’s syndrome: a consensus statement, J Clin Endocrinol Metabol, 88, 5593, 10.1210/jc.2003-030871 Newell-Price, 2006, Cushing’s syndrome, Lancet, 367, 1605, 10.1016/S0140-6736(06)68699-6 Tiemensma, 2010, Increased prevalence of psychopathology and maladaptative personality traits after long cure of Cushing’s syndrome, J Clin Endocrinol Metabol, 95, 129, 10.1210/jc.2010-0512 Valassi, 2011, ERCUSYN Study Group. The European Registry on Cushing’s Syndome: 2-year experience. Baseline demographic and clinical characteristics, Eur J Endocrinol, 165, 383, 10.1530/EJE-11-0272 Valassi, 2012, Clinical consequences of Cushing’s syndrome, Pituitary, 15, 319, 10.1007/s11102-012-0394-8 Ragnarsson, 2019, Overall and disease-specific mortality in patients with Cushing’s disease: a Swedish nationwide study, J Clin Endocrinol Metabol, 104, 2375, 10.1210/jc.2018-02524 Crispin 1993, Study protocol for the World health organization project to develop a quality of life assessment instrument (WHOQOL), Qual Life Res, 2, 153, 10.1007/BF00435734 Ebrahim, 1995, Clinical and public health perspectives and applications of health-related quality of life measurement, Soc Sci Med, 41, 1383, 10.1016/0277-9536(95)00116-O Ho, 2018, Quality of life in patients with adrenal diseases: a systematic review, Clin Endocrinol, 89, 119, 10.1111/cen.13719 Santos, 2019, Quality of life in patients with Cushing’s disease, Front Endocrinol, 10, 1, 10.3389/fendo.2019.00862 Webb, 2018, Quality of life in Cushing’s disease: a long-term issue?, Ann Endocrinol, 79, 132, 10.1016/j.ando.2018.03.007 Santos, 2012, Psychometric performance of the CushingQoL questionnaire in conditions of real clinical practice, Eur J Endocrinol, 167, 337, 10.1530/EJE-12-0325 Webb, 2008, Evaluation of Health-related quality of life in patients with Cushing’s syndrome with a new questionnaire, Eur J Endocrinol, 158, 623, 10.1530/EJE-07-0762 Milian, 2012, The development of the Tuebingen Cushing’s disease quelity of life inventory (Tuebingen CD-25). Part II: normative data from 1784 healthy people, Clin Endocrinol, 76, 861, 10.1111/j.1365-2265.2011.04280.x Milian, 2015, Validation of the Tuebingen CD-25 inventory as a measure of postoperative Health-realted quality of life in patients treated for Cushing’s disease, Neuroendocrinology, 102, 60, 10.1159/000431022 Cusimano, 2020, Development and validation of the disease-specific QOL-CD quality of life questionnaire for patients with Cushing’s disease, Neurosurg Focus, 48, E4, 10.3171/2020.3.FOCUS2044 Fitzpatrick, 1998, Evaluating patient-based outcome measures for use in clinical trials, Health Technol Assess (Winchester, Engl), 2, 1 Sonino, 2001, Psychiatric disorders associated with Cushing’s syndrome: epidemiology, pathophysiology and treatment, CNS Drugs, 15, 361, 10.2165/00023210-200115050-00003 Johnson, 2003, Vance ML Quality of life in patients with a pituitary adenoma, Pituitary, 6, 81, 10.1023/B:PITU.0000004798.27230.ed Gotch, 1994, Cushing’s syndrome from the patient perspective, Endocrinol Metab Clin N Am, 23, 607, 10.1016/S0889-8529(18)30087-2 Keskin, 2018, Sexual function in women with Cushing’s syndrome: a controlled study, Turk J Urol, 44, 287 Lobatto, 2018, Work disability and its determinants in patients with pituitary tumor-related disease, Pituitary, 21, 593, 10.1007/s11102-018-0913-3 Lindsay, 2006, Long-term impaired quality of life in Cushing’s syndrome despite clinical improvement after surgical remission, J Clin Endocrinol Metabol, 91, 447, 10.1210/jc.2005-1058 Winter, 2018, Assessing differences in how the CushingQoL is interpreted across countries: comparing patients from the US and The Netherlands, Front Endocrinol, 9, 368, 10.3389/fendo.2018.00368 Abraham, 2013, A direct comparison of quality in obese and Cushing’s syndrome patients, Eur J Endocrinol, 168, 786, 10.1530/EJE-12-1078 Van Aken, 2005, Quality of life in patients after long-term biochemical cure of Cushing’s disease, J Clin Endocrinol Metabol, 90, 3279, 10.1210/jc.2004-1375 Wagenmakers, 2012, Impaired quality of life in patients in long-term remission of Cushing’s syndrome of both adrenal and pituitary orif¡gin;a remaining effect of long-standing hypercortisolism?, Eur J Endocrinol, 167, 687, 10.1530/EJE-12-0308 Broersen, 2019, Improvement but no normalization of quality of life and cognitive functioning after treatment of Cushing’s syndrome, J Clin Endocrinol Metabol, 104, 5325 Valassi, 2018, Worse health-related quality of life at long-term follow-up in patients with Cushing’s disease than patients with cortisol producing adenoma. Data from the ERCUSYN, Clin Endocrinol (Oxford), 88, 787, 10.1111/cen.13600 Andela, 2015, Quality of life (QoL) impairments in patients with a pituitary adenoma: a systematic review of QoL studies, Pituitary, 18, 752, 10.1007/s11102-015-0636-7 Webb, 2017, Quality of life tools for the management of pituitary disease, Eur J Endocrinol, 177, R13, 10.1530/EJE-17-0041 Sippel, 2008, Waiting for change: symptom resolution after adrenalectomy for Cushing’s syndrome, Surgery, 144, 1054s1061, 10.1016/j.surg.2008.08.024 Vermalle, 2018, Lack of functional remission in Cushing’s syndrome, Endocrine, 61, 518, 10.1007/s12020-018-1664-7 Carluccio, 2015, Predictors of quality of life in 102 patients with treated Cushing’s disease, Clin Endocrinol, 82, 404, 10.1111/cen.12521 Tiemensma, 2011, Coping strategies in patients after treatment for functioning or nonfunctioning pituitary adenomas, J Clin Endocrinol Metabol, 96, 964, 10.1210/jc.2010-2490 Tiemensma, 2011, Negative illness perceptions are associated with impaired quality of life in patients after long-term remission of Cushing’s syndrome, Eur J Endocrinol, 165, 527, 10.1530/EJE-11-0307 Smith, 2009, Bilateral adrenalectomy for refractory Cushing’s disease: a safe and definitive therapy, J Am Coll Surg, 208, 1059, 10.1016/j.jamcollsurg.2009.02.054 Colao, 1999, Persistence of increased cardiovascular risk in patients with Cushing’s disease after five years of successful cure, J Clin Endocrinol Metabol, 84, 2664 Clayton, 2016, Mortality in patients with Cushing’s disease more than 10 years after remission: a multicentre, multinational, retrospective cohort study, Lancet Diabetes Endocrinol, 4, 569, 10.1016/S2213-8587(16)30005-5 Gokosmanoglu, 2017, Increased prevalence of obstructive sleep apnea in patients with Cushing’s syndrome compared with weight-and age- matched controls, Eur J Endocrinol, 176, 267, 10.1530/EJE-16-0815 Martel, 2019 Pikkarainen, 1999, The survival and well-being of patients treated for Cushing’s syndrome, J Intern Med, 245, 463, 10.1046/j.1365-2796.1999.00483.x Papoian, 2016, Patients’ perception on clinical outcome and quality of life after a diagnosis of Cushing’s syndrome, Endocr Pract, 22, 51, 10.4158/EP15855.OR Rubinstein, 2020, Time to diagnosis in Cushing’s syndrome: a meta-analysis based on 5367 patients, J Clin Endocrinol Metabol, 105, dgz136, 10.1210/clinem/dgz136 Kreitschmann-Andermahr, 2018, Support needs of patients with Cushing’s disease and Cushing’s syndrome: results of a survey conducted in Germany and the USA, Int J Endocrinol, 2018, 9014768, 10.1155/2018/9014768 De Bucy, 2017, Health-related quality of life of patients with hypothalamic-pituitary-adrenal axis dysregulation: a cohort study, Eur J Endocrinol, 177, 1, 10.1530/EJE-17-0048 Nagesser, 2000, Long-term results of total adrenalectomy for Cushing’s disease, World J Surg, 24, 108, 10.1007/s002689910020 Thompson, 2007, Improved quality of life after bilateral adrenalectomy for Cushingt’s disease: a 10-year experience, Ann Surg, 245, 790, 10.1097/01.sla.0000251578.03883.2f Oßwald, 2014, Favorable long-term outcomes of bilateral adrenalectomy in Cushing’s disease, Eur J Endocrinol, 171, 209, 10.1530/EJE-14-0214 Papakokkinou, 2020, Excess morbidity persists in patients with Cushing’s disease during long-term remission: a Swedish Nationwide Study, J Clin Endocrinol Metab, 105, dgaa291, 10.1210/clinem/dgaa291 Malik, 2003, Assessment of quality of life in adults receiving long-term growth hormone replacement compared to control subjects, Clin Endocrinol (Oxford), 59, 75, 10.1046/j.1365-2265.2003.01799.x Feldt-Rasmussen, 2002, Growth hormone deficiency and replacement in hypopituitary patients previously treated for acromegaly or Cushing’s disease, Eur J Endocrinol, 146, 67, 10.1530/eje.0.1460067 Hahner, 2007, Impaired subjective health status in 256 patients with adrenal insufficiency on standard therapy based on cross-sectional analysis, J Clin Endocrinol Metabol, 92, 3912, 10.1210/jc.2007-0685 Berr, 2015, Time to recovery of adrenal function after curative surgery for Cushing’s syndrome depends on etiology, J Clin Endocrinol Metabol, 100, 1300, 10.1210/jc.2014-3632 Starkman, 2013, Neuropsychiatric findings in Cushing’s syndrome and exogenous glucocorticoid administration, Endocrinol Metab Clin N Am, 42, 477, 10.1016/j.ecl.2013.05.010 Pivonello, 2015, Neuropsychiatric disorders in Cushing’s syndrome, Front Neurosci, 9, 1, 10.3389/fnins.2015.00129 Andela, 2015, Mechanisms in endocrinology: Cushing’s syndrome causes irreversible effects on the human brain: a systematic review of structural and functional magnetic resonance imaging studies, Eur J Endocrinol, 173, R1, 10.1530/EJE-14-1101 Starkman, 1992, Hippocampal formation volume, memory dysfunction, and cortisol levels in patients with Cushing’s syndrome, Biol Psychiatr, 32, 756, 10.1016/0006-3223(92)90079-F Simmons, 2000, Crerebral atrophy in Cushing’s disease, Surg Neurol, 53, 72, 10.1016/S0090-3019(99)00197-4 Santos, 2017, Depression and anxiety scores are associated with amygdala volume in Cushing’s syndrome: preliminary study, BioMed Res Int, 2017, 2061935, 10.1155/2017/2061935 Santos, 2014, Small cerebellar cortex volume in patients with active Cushing’s syndrome, Eur J Endocrinol, 171, 461, 10.1530/EJE-14-0371 Sonino, 1998, Clinical correlates of major depression in Cushing’s disease, Psychopathology, 31, 302, 10.1159/000029054 Starkman, 1981, Depressed mood and other psychiatric manifestations of Cushing’s syndrome: relationship to hormone levels, Psychosom Med, 43, 3, 10.1097/00006842-198102000-00002 Dorn, 1997, The longitudinal course of psychopathology in Cushing’s syndrome after correction of hypercortisolism, J Clin Endocrinol Metabol, 82, 912 Kelly, 1996, A prospective study of psychiatric and psychological aspects of Cushing’s syndrome, Clin Endocrinol, 45, 715, 10.1046/j.1365-2265.1996.8690878.x Piasecka, 2020, Psychiatric and neurocognitive consequences of endogenous hypercortisolism, J Intern Med, 288, 168, 10.1111/joim.13056 Valassi, 2017, Affective alterations in patients with Cushing’s syndrome in remission are associated with decreased BDNF and cortisone levels, Eur J Endocrinol, 176, 221, 10.1530/EJE-16-0779 Brummelman, 2012, Cognitive performance after postoperative pituitary radiotherapy: a dosimetric study of the hippocampus and the prefrontal cortex, Eur J Endocrinol, 166, 171, 10.1530/EJE-11-0749 Lecumberri, 2015, Neurocognitive long-term impact of two-field conventional radiotherapy in adult patients with operated pituitary adenomas, Pituitary, 18, 782, 10.1007/s11102-015-0653-6 Webb, 2014, Treatment effectiveness of pasireotide on health-related quality of life in patients with Cushing’s disease, Eur J Endocrinol, 171, 89, 10.1530/EJE-13-1013 van der Pas, 2012, Cortisol diurnal rhythm and quality of life after successful medical treatment of Cushing’s disease, Endocr Relat Cancer, 19, R205, 10.1530/ERC-12-0191 Fleseriu, 2012, Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing’s syndrome, J Clin Endocrinol Metabol, 97, 2039, 10.1210/jc.2011-3350 Fleseriu, 2019, Efficacy and safety of levoketoconazole in the treatment of endogenous Cushing’s syndrome (SONICS): a phase 3, multicentre, open-label, single-arm trial, Lancet Diabetes Endocrinol, 7, 855, 10.1016/S2213-8587(19)30313-4 Pivonello, 2020, Efficacy and safety of osilodrostat in patients with Cushing’s disease (LINC3): a multicentre phase III study with a double –blind, randomised withdrawal phase, Lancet Diabetes Endocrinol, 8, 748, 10.1016/S2213-8587(20)30240-0 Ragnarsson, 2014, Common genetic variants in the glucocorticoid receptor and the 11beta-hydroxysteroid dehydrogenase type 1 genes influence long-term cognitive impairments in patients with Cushing’s syndrome in remission, J Clin Endocrinol Metabol, 99, E1802, 10.1210/jc.2014-1906 Glad, 2017, Reduced DNA methylation and psychopathology following endogenous hypercortisolism. A genome-wide study, Sci Rep, 7, 44445, 10.1038/srep44445 Andela, 2015, Towards a better quality of life (QoL) for patients with pituitary diseases: results from a focus group study exploring QoL, Pituitary, 18, 86, 10.1007/s11102-014-0561-1 Albarel, 2020, Evaluation of an individualized education program in pituitary diseases: a pilot study, Eur J Endocrinol, 183, 551, 10.1530/EJE-20-0652 Andela, 2017, Enhanced self-efficacy after a self-management programme in pituitary disease: a randomized controlled trial, Eur J Endocrinol, 177, 59, 10.1530/EJE-16-1015 Martínez-Momblán, 2016, A specific nursing educational program in patients with Cushing’s syndrome, Endocrine, 53, 199, 10.1007/s12020-015-0737-0